Valuation: Nexstim Plc

Market Cap 74.69M 86.28M 69.63M 64.06M 121M 8.21B 122M 818M 321M 4.11B 324M 317M 13.61B P/E 2026 *
77.1x
P/E 2027 * 34.3x
Enterprise Value 72.59M 83.85M 67.67M 62.26M 117M 7.98B 119M 795M 312M 4B 315M 308M 13.22B EV / Sales 2026 *
5.72x
EV / Sales 2027 * 4.41x
Free-Float
58.2%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 50 11/02/2020
Director of Finance/CFO 40 11/02/2020
Chief Tech/Sci/R&D Officer 65 01/01/2008
Director TitleAgeSince
Director/Board Member 64 11/11/2019
Chairman 63 11/11/2019
Director/Board Member 55 01/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 87.51M
+2.32%+0.25%+23.85%+5.32% 209B
+2.51%+0.31%+1.11%-21.63% 137B
+1.88%+3.70%-22.38%+21.30% 130B
-2.75%+3.65%-55.30%-5.88% 71.14B
-0.70%+6.32%+11.09%+11.84% 51.59B
+0.62%+9.24%-15.14%-20.39% 49.99B
+1.37%+0.41%+22.88%+11.73% 39.31B
+0.99%+4.19%+40.06%+37.98% 38.89B
+0.40%+7.21%-23.13%+24.98% 32.19B
Average +0.66%+3.19%-1.88%+7.25% 84.33B
Weighted average by Cap. +1.29%+1.42%-0.24%+3.74%

Financials

2026 *2027 *
Net sales 12.7M 14.67M 11.84M 10.89M 20.55M 1.4B 20.79M 139M 54.62M 699M 55.1M 53.88M 2.31B 16.1M 18.6M 15.01M 13.81M 26.05M 1.77B 26.36M 176M 69.24M 886M 69.85M 68.31M 2.93B
Net income 1M 1.16M 932K 858K 1.62M 110M 1.64M 10.95M 4.3M 55.05M 4.34M 4.24M 182M 2.2M 2.54M 2.05M 1.89M 3.56M 242M 3.6M 24.1M 9.46M 121M 9.54M 9.33M 401M
Net Debt -2.1M -2.43M -1.96M -1.8M -3.4M -231M -3.44M -23M -9.03M -116M -9.11M -8.91M -383M -3.7M -4.27M -3.45M -3.17M -5.99M -407M -6.06M -40.53M -15.91M -204M -16.05M -15.7M -674M
Logo Nexstim Plc
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Employees
40
Trader
Investor
Global
Quality
ESG MSCI
-